Evidence map›Paper›PMID 31713011›Full record

ArticleDiabetologia2020

Autoimmunity plays a role in the onset of diabetes after 40 years of age.

Olov Rolandsson, Christiane S Hampe, Stephen J Sharp, Eva Ardanaz, Heiner Boeing, Guy Fagherazzi, Francesca Romana Mancini, Peter M Nilsson, Kim Overvad, Maria-Dolores Chirlaque and 19 more

Open access · hybridAbstract read
In one paragraph

Article in Diabetologia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors at 20 institutions in 9 countries.

Olov RolandssonDepartment of Public Health and Clinical Medicine, Family Medicine, Umeå University, 901 87, Umeå, Sweden. olov.rolandsson@umu.se.ORCID http://orcid.org/0000-0002-1341-6828
Christiane S HampeDepartment of Medicine, Division of Metabolism, Endocrinology and Nutrition, University of Washington, Seattle, WA, USA.
Stephen J SharpMRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge, UK.
Eva ArdanazNavarre Public Health Institute, Pamplona, Spain.
Heiner BoeingDepartment of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
Guy FagherazziCESP, Faculty of Medicine - University Paris-South, Faculty of Medicine Inserm U1018, University Paris-Saclay, Villejuif, France.
Francesca Romana ManciniCESP, Faculty of Medicine - University Paris-South, Faculty of Medicine Inserm U1018, University Paris-Saclay, Villejuif, France.
Peter M NilssonDepartment of Clinical Sciences, Clinical Research Center, Skåne University Hospital, Lund University, Malmö, Sweden.
Kim OvervadDepartment of Public Health, Aarhus University, Aarhus, Denmark.
Maria-Dolores ChirlaqueConsortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Publica), Madrid, Spain.
Miren DorronsoroConsortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Publica), Madrid, Spain.
Marc J GunterInternational Agency for Research on Cancer, Lyon, France.
Rudolf KaaksDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Timothy J KeyCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Kay-Tee KhawDepartment of Public Health and Primary Care, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
Vittorio KroghEpidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Tilman KühnDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Domenico PalliInstitute for Cancer Research, Prevention and Clinical Network - ISPRO, Florence, Italy.
Salvatore PanicoDipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy.
Carlotta SacerdoteUnit of Cancer Epidemiology, Azienda Ospedaliera Universitaria (AOU) Citta' della Salute e della Scienza Hospital-University of Turin and Center for Cancer Prevention (CPO), Torino, Italy.
Maria-José SánchezConsortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Publica), Madrid, Spain.
Gianluca SeveriInserm, Center for Research in Epidemiology and Population Health (CESP), Université Paris-Sud, Université Paris-Saclay, University of Versailles Saint-Quentin-en-Yvelines (UVSQ) Gustave Roussy, Villejuif, France.
Annemieke M W SpijkermanNational Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Rosario TuminoCancer Registry and Histopathology Department, 'Civic - M.P. Arezzo' Hospital, Ragusa, Italy.
Yvonne T van der SchouwJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.
Elio RiboliSchool of Public Health, Imperial College London, London, UK.
Nita G ForouhiMRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge, UK.
Claudia LangenbergMRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge, UK.
Nicholas J WarehamMRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge, UK.
University of Cambridge · GBGerman Cancer Research Center · DEInserm · FRAarhus University · DKAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITBasque Government · ESCentre international de recherche sur le cancer · FRFederico II University Hospital · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITGerman Institute of Human Nutrition · DEImperial College London · GBInstituto Murciano de Investigación Biosanitaria · ESIstituto per la Ricerca Sociale · ITLund University · SENational Institute for Public Health and the Environment · NLNavarre Institute of Health Research · ESUmeå University · SEUniversidad de Granada · ESUniversité Paris-Sud · FRUniversity Medical Center Utrecht · NL

Funding

ISLET CELL MEMBRANE ANTIBODIES IN DIABTESR01DK026190 · NIDDK · UNIVERSITY OF WASHINGTON · PI HAMPE, CHRISTIANE S · 1986 to 2016
$4.9M
Cancer Research UK 14136Medical Research Council G0401527Medical Research Council G1000143Medical Research Council MC_UU_12015/1Medical Research Council MC_UU_12015/5Medical Research Council MR/N003284/1NIDDK NIH HHS R01 DK026190World Health Organization 001
6 · The paper itself

Abstract

aims/hypothesisType 1 and type 2 diabetes differ with respect to pathophysiological factors such as beta cell function, insulin resistance and phenotypic appearance, but there may be overlap between the two forms of diabetes. However, there are relatively few prospective studies that have characterised the relationship between autoimmunity and incident diabetes. We investigated associations of antibodies against the 65 kDa isoform of GAD (GAD65) with type 1 diabetes and type 2 diabetes genetic risk scores and incident diabetes in adults in European Prospective Investigation into Cancer and Nutrition (EPIC)-InterAct, a case-cohort study nested in the EPIC cohort.

methodsGAD65 antibodies were analysed in EPIC participants (over 40 years of age and free of known diabetes at baseline) by radioligand binding assay in a random subcohort (n = 15,802) and in incident diabetes cases (n = 11,981). Type 1 diabetes and type 2 diabetes genetic risk scores were calculated. Associations between GAD65 antibodies and incident diabetes were estimated using Prentice-weighted Cox regression.

resultsGAD65 antibody positivity at baseline was associated with development of diabetes during a median follow-up time of 10.9 years (HR for GAD65 antibody positive vs negative 1.78; 95% CI 1.43, 2.20) after adjustment for sex, centre, physical activity, smoking status and education. The genetic risk score for type 1 diabetes but not type 2 diabetes was associated with GAD65 antibody positivity in both the subcohort (OR per SD genetic risk 1.24; 95% CI 1.03, 1.50) and incident cases (OR 1.97; 95% CI 1.72, 2.26) after adjusting for age and sex. The risk of incident diabetes in those in the top tertile of the type 1 diabetes genetic risk score who were also GAD65 antibody positive was 3.23 (95% CI 2.10, 4.97) compared with all other individuals, suggesting that 1.8% of incident diabetes in adults was attributable to this combination of risk factors. CONCLUSIONS/

interpretationOur study indicates that incident diabetes in adults has an element of autoimmune aetiology. Thus, there might be a reason to re-evaluate the present subclassification of diabetes in adulthood.

Indexed as

AdultAgedAntibodiesAutoimmunityCase-Control StudiesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2FemaleGlutamate DecarboxylaseHumansMaleMiddle AgedAntibodiesGlutamate Decarboxylaseglutamate decarboxylase 2AutoantibodyAutoimmunityGenetic risk scoreIncident diabetesType 1 diabetesType 2 diabetes

Identifiers

PMID31713011
PMCPMC6946728
OpenAlexW2986133512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.